Initially, post the 2000s, drug discovery research drove innovation activity by stressing on in-house R&D capabilities for close to 30 domestic pharmaceutical firms . However, the engagement of domestic pharmaceutical firms with drug discovery for new drug development has been on the decline from 2012. The number of patents filed on new chemical entities (NCEs) by the domestic pharmaceutical firms is small . Presently, there are only three firms pursuing some activity in drug discovery and new drug development .
Read the paper.
Read the paper.
No comments:
Post a Comment